Overview
Welcome to Immunicum's Investor Relations pages! Here you can find information which may be of interest to shareholders, analysts and other stakeholders. If you need more information or have any questions, please contact Sven Rohmann, CEO.
Phone: +46(0)8 732 8400
Email: ir@immunicum.com
CEO statement, Q2 2020
“Our efforts during the second quarter of 2020 have been focused on key regulatory interactions, the continuation of the ongoing Phase Ib/II ILIAD combination trial, as well as strategic preparations to advance our off-the-shelf immune primer, ilixadencel.In August we also announced an update on survival from the MERECA trial. The new set of data confirmed that the final median Overall Survival (OS) for the sunitinib control group had been reached at 25.3 months. Meanwhile, the median OS has not yet been reached in the ilixadencel treatment group, indicating a survival benefit in the study’s co-primary endpoint. In addition, all five Complete Responders (CRs) in the ilixadencel treatment group were still alive in this follow-up, while the one CR in the control group died during the first follow-up period.”
– Alex Karlsson-Parra, interim CEO
To read the full report, please click here
Investor Downloads
